BIOVIE INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BIOVIE INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($17.54M) | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | ($32.12M) | Aug 15, 2025 |
| FY2024 | Jun 30, 2023 | ($50.26M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($26.08M) | Aug 16, 2023 |
| FY2022 | Jun 30, 2021 | ($130.25M) | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | ($16.68M) | Aug 30, 2021 |
| FY2018 | Jun 30, 2018 | ($2.43M) | Oct 5, 2018 |
| FY2018 | Jun 30, 2017 | ($1.33M) | Oct 5, 2018 |
| FY2017 | Jun 30, 2016 | ($431.9K) | Aug 24, 2017 |
| FY2016 | Jun 30, 2015 | ($233.0K) | Sep 28, 2016 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($18.07M) | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | ($32.18M) | Aug 15, 2025 |
| FY2024 | Jun 30, 2023 | ($45.08M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($27.25M) | Aug 16, 2023 |
| FY2022 | Jun 30, 2021 | ($138.05M) | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | ($2.69M) | Aug 30, 2021 |
| FY2020 | Jun 30, 2019 | ($2.50M) | Aug 7, 2020 |
| FY2018 | Jun 30, 2018 | ($2.37M) | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | ($1.55M) | Oct 5, 2018 |
| FY2017 | Jun 30, 2016 | ($432.0K) | Aug 24, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $9.27M | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $23.10M | Aug 15, 2025 |
| FY2024 | Jun 30, 2023 | $33.30M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $17.26M | Aug 16, 2023 |
| FY2022 | Jun 30, 2021 | $2.54M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $1.15M | Aug 30, 2021 |
| FY2020 | Jun 30, 2019 | $1.01M | Aug 7, 2020 |
| FY2018 | Jun 30, 2018 | $370.9K | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | $466.4K | Oct 5, 2018 |
| FY2017 | Jun 30, 2016 | $37.9K | Aug 24, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $8.57M | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $8.85M | Aug 15, 2025 |
| FY2024 | Jun 30, 2023 | $11.55M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $9.77M | Aug 16, 2023 |
| FY2022 | Jun 30, 2021 | $4.64M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $1.31M | Aug 30, 2021 |
| FY2020 | Jun 30, 2019 | $1.26M | Aug 7, 2020 |
| FY2018 | Jun 30, 2018 | $1.77M | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | $69.1K | Oct 5, 2018 |
| FY2017 | Jun 30, 2016 | $15.3K | Aug 24, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($19.03M) | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | ($27.95M) | Aug 15, 2025 |
| FY2024 | Jun 30, 2023 | ($40.25M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($18.99M) | Aug 16, 2023 |
| FY2022 | Jun 30, 2021 | ($10.45M) | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | ($1.63M) | Aug 30, 2021 |
| FY2020 | Jun 30, 2019 | ($2.50M) | Aug 7, 2020 |
| FY2018 | Jun 30, 2018 | ($621.3K) | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | ($623.6K) | Oct 5, 2018 |
| FY2017 | Jun 30, 2016 | ($153.6K) | Aug 24, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $21.56M | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $25.21M | Aug 15, 2025 |
| FY2024 | Jun 30, 2023 | $35.10M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $20.11M | Aug 16, 2023 |
| FY2022 | Jun 30, 2021 | $6.05M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $2.08M | Aug 30, 2021 |
| FY2020 | Jun 30, 2019 | $2.57M | Aug 7, 2020 |
| FY2018 | Jun 30, 2018 | $2.18M | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | $2.36M | Oct 5, 2018 |
| FY2017 | Jun 30, 2016 | $2.72M | Aug 24, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $2.55M | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $9.70M | Aug 15, 2025 |
| FY2024 | Jun 30, 2023 | $19.76M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $16.44M | Aug 16, 2023 |
| FY2022 | Jun 30, 2021 | $996.4K | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $23.58M | Aug 30, 2021 |
| FY2020 | Jun 30, 2019 | $443.5K | Aug 7, 2020 |
| FY2018 | Jun 30, 2018 | $2.06M | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | $1.21M | Oct 5, 2018 |
| FY2017 | Jun 30, 2016 | $803.2K | Aug 24, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $19.01M | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $15.51M | Aug 15, 2025 |
| FY2025 | Jun 30, 2023 | $15.34M | Aug 15, 2025 |
| FY2024 | Jun 30, 2022 | $3.67M | Sep 30, 2024 |
| FY2023 | Jun 30, 2021 | $5.05M | Aug 16, 2023 |
| FY2022 | Jun 30, 2020 | ($21.50M) | Sep 27, 2022 |
| FY2021 | Jun 30, 2019 | $2.13M | Aug 30, 2021 |
| FY2018 | Jun 30, 2018 | $111.2K | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | $1.16M | Oct 5, 2018 |
| FY2017 | Jun 30, 2016 | $1.92M | Aug 24, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $345.7K | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $345.7K | Aug 15, 2025 |
| FY2024 | Jun 30, 2023 | $345.7K | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $345.7K | Aug 16, 2023 |
| FY2022 | Jun 30, 2021 | $345.7K | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | $345.7K | Aug 30, 2021 |
| FY2020 | Jun 30, 2019 | $345.7K | Aug 7, 2020 |
| FY2018 | Jun 30, 2018 | $345.7K | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | $345.7K | Oct 5, 2018 |
| FY2017 | Jun 30, 2016 | $345.7K | Aug 24, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($352.14M) | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | ($334.23M) | Aug 15, 2025 |
| FY2024 | Jun 30, 2023 | ($301.23M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($250.97M) | Aug 16, 2023 |
| FY2022 | Jun 30, 2021 | ($224.89M) | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | ($41.04M) | Aug 30, 2021 |
| FY2020 | Jun 30, 2019 | ($7.26M) | Aug 7, 2020 |
| FY2018 | Jun 30, 2018 | ($4.77M) | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | ($2.34M) | Oct 5, 2018 |
| FY2017 | Jun 30, 2016 | ($1.00M) | Aug 24, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $17.54M | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $23.84M | Aug 15, 2025 |
| FY2024 | Jun 30, 2023 | $19.46M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $18.64M | Aug 16, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | (12) | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | (73) | Aug 15, 2025 |
| FY2024 | Jun 30, 2023 | (15) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | (1) | Aug 16, 2023 |
| FY2022 | Jun 30, 2021 | (14) | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | (6) | Aug 30, 2021 |
| FY2020 | Jun 30, 2019 | 0 | Aug 7, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | (12) | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | (73) | Aug 15, 2025 |
| FY2024 | Jun 30, 2023 | (15) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | (1) | Aug 16, 2023 |
| FY2022 | Jun 30, 2021 | (14) | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | (6) | Aug 30, 2021 |
| FY2020 | Jun 30, 2019 | 0 | Aug 7, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 1.91M | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | 619,008 | Aug 15, 2025 |
| FY2024 | Jun 30, 2023 | 3.64M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | 24.98M | Aug 16, 2023 |
| FY2022 | Jun 30, 2021 | 22.33M | Sep 27, 2022 |
| FY2021 | Jun 30, 2020 | 5.20M | Aug 30, 2021 |
| FY2020 | Jun 30, 2019 | 4.06M | Aug 7, 2020 |
| FY2018 | Jun 30, 2018 | 98.50M | Sep 27, 2019 |
| FY2018 | Jun 30, 2017 | 91.93M | Oct 5, 2018 |
| FY2017 | Jun 30, 2016 | 87.16M | Aug 24, 2017 |